Active Cancer Digestion, Kidneys & Other Organs

A novel non-invasive DNA methylation test for melanoma

Summary

Original abstract (not yet simplified)

Early cancer detection is a key to improve survival rates. For melanoma the survival falls from >98% at Stage 1 to 22% at Stage 4.Currently, skin biopsy is the only method of melanoma detection. It is an expensive and invasive procedure. Our patented technology, is a combination of a unique non-invasive tape strip skin sample collection technique and proprietary DNA...

View original technical description
Early cancer detection is a key to improve survival rates. For melanoma the survival falls from >98% at Stage 1 to 22% at Stage 4.Currently, skin biopsy is the only method of melanoma detection. It is an expensive and invasive procedure. Our patented technology, is a combination of a unique non-invasive tape strip skin sample collection technique and proprietary DNA methylation panel specific for melanoma. This will allow quick and inexpensive testing for melanoma at GP level and as an at-home test kit.Our proof of concept study with Guy’s Hospital (UK) showed over 95% specificity and 85% sensitivity in detecting melanoma compared to standard biopsy procedures.Mitra Bio is a female-led team of 6 scientists and business developers with experience in building diagnostics platforms. We aim to improve melanoma detection and reduce melanoma health and economic burden, which currently results in 15K deaths/year in the EU.

Related Research

Grants with similar aims, by meaning.

Development of a non-invasive molecular diagnosis tool for skin-cancer detection
Feasibility study investigating circulating peripheral mitochondrial DNA as a potential non-invasive biomarker for diagnosis and surveillance of high risk cutaneous melanoma
DETECTION-2 feasibility: A feasibility trial to assess recruitment rates and ctDNA reporting times for patients with resected stage IIB/IIC/IIIA melanoma
MMD PCR for lung cancer driver mutations
A feasibility trial to assess recruitment rates and ctDNA reporting times for patients with resected stage IIB/IIC/IIIA melanoma

Original classification

HORIZON

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.